Skip to content
10-Q

Quarterly Report

Elicio Therapeutics, Inc. ELTX

0001601485-25-000074

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 16M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $11.41M
Current Liabilities Q1 2025 · Dec 31, 2024 $11.52M
Total Liabilities Q1 2025 · Mar 31, 2025 $19.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $39.49M
Current Assets Q1 2025 · Mar 31, 2025 $20.94M
Current Assets Q1 2025 · Dec 31, 2024 $20.69M
Total Assets Q1 2025 · Mar 31, 2025 $28.14M
Total Assets Q1 2025 · Dec 31, 2024 $28.18M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $17.62M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $11.85M
Shares Diluted Q1 2025 · Mar 31, 2024 10.27M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$12.12M
Stockholders Equity Q1 2025 · Mar 31, 2024 $4.87M
Stockholders Equity Q1 2025 · Dec 31, 2023 $11.37M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.15
Eps Basic Q1 2025 · Mar 31, 2024 −$1.15
Sga Expense Q1 2025 · Mar 31, 2024 $2.68M
Rd Expense Q1 2025 · Mar 31, 2024 $7.56M
Net Income Q1 2025 · Mar 31, 2024 −$11.83M
Operating Income Q1 2025 · Mar 31, 2024 −$10.24M